GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » IMRIS Inc (GREY:IMRSQ) » Definitions » Valuation Rank

IMRIS (IMRSQ) Valuation Rank


View and export this data going back to 2010. Start your Free Trial

What is IMRIS Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


IMRIS Valuation Rank Related Terms

Thank you for viewing the detailed overview of IMRIS's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


IMRIS (IMRSQ) Business Description

Traded in Other Exchanges
N/A
Address
100-1370 Sony Place, Winnipeg, MB, CAN, R3T 1N5
IMRIS Inc designs, manufactures and markets Image-guided therapy systems that improves the effectiveness of therapy delivery. Its main product is the Visius surgical theater. The company provides its products to hospitals that deliver clinical services to patients in the neurosurgical, spinal, cerebrovascular and cardiovascular markets. The firm is focused on bringing enhanced visualization to the point of therapy delivery and is spread across Canada, United States, Europe and the Middle East and Asia-Pacific.